Munich \u2014 Scin\u00adto\u00admics GmbH has sold its stake in Pentix\u00ada\u00adPh\u00adarm GmbH to Eckert & Zieg\u00adler Strah\u00adlen- und Medi\u00adzin\u00adtech\u00adnik AG. It was advi\u00adsed on the tran\u00adsac\u00adtion by G\u00fctt Olk Feld\u00adhaus (GOF). Part of the conside\u00adra\u00adtion consis\u00adted of shares in Eckert & Zieg\u00adler. The parties have agreed not to disc\u00adlose the purchase price.<\/p>\n
Pentix\u00ada\u00adPh\u00adarm is deve\u00adlo\u00adping a radio\u00adphar\u00admaceu\u00adti\u00adcal combi\u00adna\u00adtion product against lymphoma and a number of rela\u00adted tumors that can be used for both the diagno\u00adsis and treat\u00adment of cancer. In Febru\u00adary 2021, Pentix\u00ada\u00adPh\u00adarm had recei\u00adved confir\u00adma\u00adtion from the Euro\u00adpean Medi\u00adci\u00adnes Agency (EMA) that its drug candi\u00addate Pentix\u00ada\u00adFor can advance directly into Phase III clini\u00adcal trials.<\/p>\n
Scin\u00adto\u00admics is active in the deve\u00adlo\u00adp\u00adment, licen\u00adsing and commer\u00adcia\u00adliza\u00adtion of radio-phar\u00admaceu\u00adti\u00adcal know-how and radio\u00adphar\u00admaceu\u00adti\u00adcals and was a foun\u00adding share\u00adhol\u00adder in PentixaPharm.<\/p>\n
Eckert & Zieg\u00adler is a listed company head\u00adquar\u00adte\u00adred in Berlin, Germany, which holds inte\u00adrests in compa\u00adnies in the fields of medi\u00adcal and isotope tech\u00adno\u00adlogy as well as radio-phar\u00admacy and nuclear medi\u00adcine, among others.<\/p>\n
Legal advi\u00adsors to Scin\u00adto\u00admics GmbH: G\u00fctt Olk Feld\u00adhaus, Munich<\/strong> About G\u00fctt Olk Feldhaus<\/strong> Munich \u2014 Scin\u00adto\u00admics GmbH has sold its stake in Pentix\u00ada\u00adPh\u00adarm GmbH to Eckert & Zieg\u00adler Strah\u00ad\u00adlen- und Medi\u00adzin\u00adtech\u00adnik AG. It was advi\u00adsed on the tran\u00adsac\u00adtion by G\u00fctt Olk Feld\u00adhaus (GOF). Part of the conside\u00adra\u00adtion consis\u00adted of shares in Eckert & Zieg\u00adler. The parties have agreed not to disc\u00adlose the purchase price. Pentix\u00ada\u00adPh\u00adarm is deve\u00adlo\u00adping a [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37293,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1372,1377],"tags":[],"class_list":["post-43469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-consultant","category-corporate-finance-ma","news-category-deals-news-en"],"yoast_head":"\n
\nAdrian von Prit\u00adt\u00adwitz (Part\u00adner, Lead), Dr. Ricarda Theis (Asso\u00adciate, both Corporate\/M&A)<\/p>\n
\nG\u00fctt Olk Feld\u00adhaus is a leading inter\u00adna\u00adtio\u00adnal law firm based in Munich. We provide compre\u00adhen\u00adsive advice on commer\u00adcial and corpo\u00adrate law. Our focus is on corpo\u00adrate law, M&A, private equity and finan\u00adcing. In these specia\u00adlist areas we also take on the litigation.<\/p>\n","protected":false},"excerpt":{"rendered":"